Outcomes in Psoriasis Clinical Trials from January 2011 to March 2012
Current Dermatology Reports, ISSN: 2162-4933, Vol: 1, Issue: 3, Page: 137-147
2012
- 1Citations
- 10Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Review Description
In clinical trials, conclusions on treatment safety and efficacy depend on the selected outcomes; therefore, it is very important to choose outcomes that are able to address meaningful aspects of the disease experience. This review analyzes 54 clinical trials of psoriasis treatments that took place from January 2011 to March 2012. The majority of the primary outcomes were based exclusively on the clinician/investigator assessment. Twenty-four percent of studies had a patient-reported measure listed as primary outcome. However, of the 34 studies reporting secondary outcomes, only seven had secondary outcomes based exclusively on the clinician/investigator assessment. Although there is a trend toward an increase in trials incorporating patient-reported measures, it is necessary to improve the quality of the measures used, and to adopt more thoroughly validated and homogeneous clinical measures and times of follow-up. © 2012 Springer Science+Business Media, LLC.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85069329799&origin=inward; http://dx.doi.org/10.1007/s13671-012-0019-5; http://link.springer.com/10.1007/s13671-012-0019-5; http://link.springer.com/content/pdf/10.1007/s13671-012-0019-5; http://link.springer.com/content/pdf/10.1007/s13671-012-0019-5.pdf; http://link.springer.com/article/10.1007/s13671-012-0019-5/fulltext.html; http://www.springerlink.com/index/10.1007/s13671-012-0019-5; http://www.springerlink.com/index/pdf/10.1007/s13671-012-0019-5; https://dx.doi.org/10.1007/s13671-012-0019-5; https://link.springer.com/article/10.1007/s13671-012-0019-5
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know